• Users Online: 241
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2017  |  Volume : 17  |  Issue : 4  |  Page : 115-118

Association of serum fibroblast growth factor-23 with conventional cardiovascular risk factors in hemodialysis patients


1 Department of Internal Medicine and Nephrology, Nephrology Unit, Assiut University Hospital, Assiut, Egypt
2 Department of Internal Medicine and Cardiology, Cardiology and Critical Care Unit, Assiut University Hospital, Assiut, Egypt
3 Department of Clinical Pathology, South Oncology Institute, Assiut, Egypt

Correspondence Address:
Dr. Walaa H Mohammad
MD in Internal Medicine, Department of Internal Medicine and Nephrology, Nephrology Unit, Assiut University Hospital, Assiut, 71515
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jesnt.jesnt_23_17

Rights and Permissions

Objectives We aimed to study the association of fibroblast growth factor-23 (FGF-23) with conventional cardiovascular risk factors in hemodialysis (HD) patients. Patients and methods This is a cross-sectional study, which was carried out on 90 HD patients. Demographic data were recorded in predefined data sheets. The blood samples for FGF-23 and other laboratory variables were collected and measured using the standard methods. The results and their relationships with FGF-23 were analyzed. Results In our study, there were insignificant correlations between FGF-23 and all clinical cardiovascular variables apart from a significant positive correlation between FGF-23 and systolic blood pressure (r=−0.546, P=0.004). Multivariate analysis failed to show any significant association between FGF-23 and systolic blood pressure (B=0.749, T=1.659, P=0.067). Conclusion Multiple linear regression analysis failed to show any significant association between FGF-23 and other conventional cardiovascular risk factors. We recommend using FGF-23 as an independent risk factor of cardiovascular morbidity and mortality, and searching for agents that control its level in HD patients.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1370    
    Printed54    
    Emailed0    
    PDF Downloaded105    
    Comments [Add]    

Recommend this journal